Deyuan Pharmaceutical announced that the company participated in the 12th batch of national drug centralized volume procurement. According to the “12th Batch of National Organization Drug Centralized Volume Procurement Proposed Selection Results Table” issued by the Joint Procurement Office, the company's sitagliptin metformin sustained-release tablets, dagliflozin metformin sustained-release tablets, pioglitone metformin tablets, fenofibrate capsules, and bisoprolol amlodipine tablets will be selected. The procurement cycle will be selected from the date of implementation of the selection results to December 31, 2029.

Deyuan Pharmaceutical announced that the company participated in the 12th batch of national drug centralized volume procurement. According to the “12th Batch of National Organization Drug Centralized Volume Procurement Proposed Selection Results Table” issued by the Joint Procurement Office, the company's sitagliptin metformin sustained-release tablets, dagliflozin metformin sustained-release tablets, pioglitone metformin tablets, fenofibrate capsules, and bisoprolol amlodipine tablets will be selected. The procurement cycle will be selected from the date of implementation of the selection results to December 31, 2029.